Targovax to present at upcoming investor and industry conferences
16 mai 2018 01h01 HE
|
Targovax ASA
Oslo, Norway, 16 May 2018 - Targovax ASA (OSE: TRVX), a clinical stage company focused on developing immuno-oncology therapies to target solid tumors, announces that members of its senior management...
Targovax ASA: First quarter 2018 results
03 mai 2018 01h03 HE
|
Targovax ASA
Oslo, Norway, 3 May 2018 - Targovax ASA (OSE: TRVX), a clinical stage company focused on developing immuno-oncology therapies to target solid tumors, today announces its first quarter 2018 results. ...
Targovax announces early signal of efficacy in ONCOS-102 trial in mesothelioma
02 mai 2018 01h01 HE
|
Targovax ASA
Responses observed in three out of six patients Recruitment into the randomized part of the trial underway Oslo, Norway, 2 May 2018 - Targovax ASA (OSE: TRVX), a clinical stage company focused...
Targovax ASA: Issuance of restricted stock units (RSUs) to the board members
25 avr. 2018 08h18 HE
|
Targovax ASA
Reference is made to the annual general meeting of Targovax ASA (the "Company") on 11 April 2018 (the "AGM") where election of members to the board of directors was according to the nomination...
Targovax presentation at ChinaBio Partnering Forum 2018
25 avr. 2018 01h01 HE
|
Targovax ASA
Oslo, Norway, 25 April 2018 - Targovax ASA (OSE: TRVX), a clinical stage company focused on developing immuno-oncology therapies to target solid tumours, have today presented at the ChinaBio...
Targovax ASA: Invitation to first quarter 2018 results presentation Thursday 3 May
24 avr. 2018 01h01 HE
|
Targovax ASA
Oslo, Norway, 24 April 2018 - Targovax ASA (OSE: TRVX), a clinical stage company focused on developing immuno-oncology therapies to target solid tumors, will announce its first quarter 2018 results...
Targovax strengthens Board of Directors with the appointment of Catherine Wheeler
12 avr. 2018 08h48 HE
|
Targovax ASA
Oslo, Norway, 12 April 2018 - Targovax ASA (OSE: TRVX), a clinical stage company focused on developing immuno-oncology therapies to target solid tumors, today announces the appointment of Catherine...
Targovax ASA: Protocol from the Annual General Meeting
11 avr. 2018 04h42 HE
|
Targovax ASA
The annual general meeting was held on April 11, 2018 at the Company's offices at Lilleakerveien 2C, 0283 Oslo. Please find minutes of the meeting attached. For further information,...
Targovax ASA: Proposal from the nomination committee to the annual general meeting 11 April 2018
24 mars 2018 04h17 HE
|
Targovax ASA
Reference is made to the notice published on 15 March 2018 regarding the annual general meeting in Targovax ASA (the "Company") to be held on 11 April 2018 at 10:00 am (CEST). The proposal by the...
Targovax ASA: Annual Report 2017
15 mars 2018 02h01 HE
|
Targovax ASA
On 14 March 2018, the board of directors of Targovax ASA approved the company's financial statements for 2017, which will be dealt with by the Company's annual general meeting on 11 April 2018. The...